Prevymis

Age 18 years and older; AND

Patient is a CMV-seropositive recipient [R+] meeting one of the following circumstances:
i) Recipient using umbilical cord blood as the stem cell source;
OR
ii) Patient is a haploidentical recipient;
OR
iii) Recipient of T-cell depleted grafts;
OR
iv) Recipient with documented history of CMV disease prior to transplantation;
OR
v) Recipient requiring high-dose steroids (defined as the use of greater than or the same as 1 mg/kg/day of prednisone or an equivalent dose of another corticosteroid) or other immunosuppression for acute graft versus host disease (GVHD);
OR
vi) Recipients treated with antithymocyte globulin (ATG) for conditioning,
OR
vii) Recipient treated with ATG for steroid-refractory acute GVHD treatment.

Patient must have undetectable CMV viremia at baseline (results should be from samples collected within a week of transplant date); AND

Treatment is prescribed by a clinician with expertise in the management of HSCT (e.g., medical oncologist, hematologist, infectious disease specialist)